Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4PUDW)

Drug Name

L-glutamic acid Drug Info

Synonyms

Aciglut; Glu; Glusate; Glut; Glutacid; Glutamicol; Glutamidex; Glutaminol; Glutaton; Gulutamine; Acide glutamique; Acido glutamico; Acidum glutamicum; Acidum glutaminicum; Glutamic acid polymer; Glutaminic acid; E 620; A-Aminoglutaric acid; A-Glutamic acid; Acide glutamique [INN-French]; Acido glutamico [INN-Spanish]; Acidum glutamicum [INN-Latin]; D-Glutamiensuur; Glutamic Acid [USAN:INN]; Glutamic acid (VAN); Glutaminic acid (VAN); Gulutamine (USP); L-Glutamic acid hydrochloride; L-Glutaminic acid; L-Glutaminsaeure; L-glu; L-glutamate; Alpha-Aminoglutaric acid (VAN); Alpha-L-Glutamic acid polymer; Glutamic Acid (L-glutamic acid); Glutamic acid (H-3); H-Glu-OH; L-2-Aminoglutaric acid; L-Glutamic acid (9CI); L-Glutamic acid (JAN); L-Glutamic acid, homopolymer; L-a-Aminoglutaric acid; L-alpha-Aminoglutaric acid; Poly-L-glutamate; Sodium Glutamate (L-glutamic Acid); Glutamic acid, L-, peptides; L-Glutamic acid, homopolymer (9CI); Poly(alpha-L-glutamic acid); Glutamic acid, L-(7CI,8CI); L-(+)-glutamic acid; (S)-(+)-Glutamic acid; (S)-2-Aminopentanedioic acid; (S)-Glutamic acid; 1-Aminopropane-1,3-dicarboxylic acid

Indication

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Approved	[1] , [2] , [3]

Therapeutic Class

Dietary supplement

Cross-matching ID

PubChem CID: 33032
ChEBI ID: CHEBI:16015
CAS Number: CAS 56-86-0
TTD Drug ID: DM4PUDW
VARIDT Drug ID: DR00005

Molecule-Related Drug Atlas

Molecule Type:

DTT

DTP

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Transported By Organic anion transporter 4 (SLC22A11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	leukaemia	2A60-2B33	Approved	[20]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[21]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[22]
Pravastatin	DM6A0X7	Hypercholesterolaemia	5C80.0	Approved	[23]
Tetracycline	DMZA017	Bacterial infection	1A00-1C4Z	Approved	[24]
Bumetanide	DMRV7H0	Congestive heart failure	BD10	Approved	[25]
Estrone sulfate	DMVBIZL	Menopausal and postmenopausal disorder	GA30	Approved	[26]
Levocetirizine	DMQYLGP	Allergy	4A80-4A85	Approved	[27]
PGF2alpha	DM4XAU7	Solid tumour/cancer	2A00-2F9Z	Clinical trial	[21]
Uric acid	DMA1MKT	Discovery agent	N.A.	Investigative	[28]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Transported By Organic anion transporting polypeptide 2B1 (SLCO2B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[29]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[30]
Etoposide	DMNH3PG	Solid tumour/cancer	2A00-2F9Z	Approved	[31]
Pravastatin	DM6A0X7	Hypercholesterolaemia	5C80.0	Approved	[32]
Atorvastatin	DMF28YC	Cardiovascular disease	BA00-BE2Z	Approved	[33]
Cerivastatin	DMXCM7H	Hyperlipidaemia	5C80	Approved	[34]
Pitavastatin calcium	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[35]
Digoxin	DMQCTIH	Arrhythmia	BC9Z	Approved	[36]
Rosuvastatin	DMMIQ7G	Hypercholesterolaemia	5C80.0	Approved	[37]
Fluvastatin	DM4MDJY	Hypercholesterolaemia	5C80.0	Approved	[38]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Transported By Vesicular glutamate transporter 2 (SLC17A6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phosphate	DMUXQG7	Constipation	DD91.1	Approved	[39]
------------------------------------------------------------------------------------

Drug(s) Transported By Vesicular glutamate transporter 1 (SLC17A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phosphate	DMUXQG7	Constipation	DD91.1	Approved	[40]
------------------------------------------------------------------------------------

Drug(s) Transported By Organic cation transporter-like 3 (SLC22A13)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aspartic acid	DMK7EYA	Discovery agent	N.A.	Investigative	[5]
------------------------------------------------------------------------------------

Drug(s) Transported By Putative sodium-coupled neutral amino acid transporter 10 (SLC38A10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aspartic acid	DMK7EYA	Discovery agent	N.A.	Investigative	[11]
------------------------------------------------------------------------------------

Drug(s) Targeting N-methyl-D-aspartate receptor (NMDAR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cycloserine	DMT1I52	Bacterial infection	1A00-1C4Z	Approved	[41]
Benzphetamine	DMIJATC	Obesity	5B81	Approved	[42]
Ketamine	DMT5HA4	Anaesthesia	9A78.6	Approved	[43]
Felbamate	DM1V5ZS	Epilepsy	8A60-8A68	Approved	[44]
Memantine	DMD9WSC	Alzheimer disease	8A20	Approved	[45]
Huperzine A	DMMAWLU	Alzheimer disease	8A20	Approved	[46]
Levorphanol	DMGS80V	Pain	MG30-MG3Z	Approved	[47]
Magnesium Sulfate	DMVEK07	Acute pain	MG31	Approved	[48]
Magnesium	DMU4ORS	Ischemic stroke	8B11.5Z	Approved	[49]
Orphenadrine	DMW542E	Parkinson disease	8A00.0	Approved	[50]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
N-methyl-D-aspartate receptor (NMDAR)	TT9IK2Z	NOUNIPROTAC	Antagonist	[4]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic cation transporter-like 3 (SLC22A13)	DT38SZL	S22AD_HUMAN	Substrate	[5]
Cystine/glutamate transporter (SLC7A11)	DTKLMH6	XCT_HUMAN	Substrate	[6]
Calcium-binding mitochondrial carrier protein Aralar2 (SLC25A13)	DTDSYAQ	CMC2_HUMAN	Substrate	[7]
Sodium-independent aspartate/glutamate transporter 1 (SLC7A13)	DTMWE5P	S7A13_HUMAN	Substrate	[8]
Calcium-binding mitochondrial carrier protein Aralar1 (SLC25A12)	DT85HYR	CMC1_HUMAN	Substrate	[9]
Putative sodium-coupled neutral amino acid transporter 8 (SLC38A8)	DT0UQDA	S38A8_HUMAN	Substrate	[10]
Putative sodium-coupled neutral amino acid transporter 10 (SLC38A10)	DT2LGOY	S38AA_HUMAN	Substrate	[11]
Excitatory amino acid transporter 4 (SLC1A6)	DTV2AOB	EAA4_HUMAN	Substrate	[12]
Excitatory amino acid transporter 1 (SLC1A3)	DT9U216	EAA1_HUMAN	Substrate	[12]
Vesicular glutamate transporter 1 (SLC17A7)	DTNK0FR	VGLU1_HUMAN	Substrate	[13]
Vesicular glutamate transporter 2 (SLC17A6)	DT5LHCR	VGLU2_HUMAN	Substrate	[13]
Mitochondrial glutamate carrier 1 (SLC25A22)	DTJCWP8	GHC1_HUMAN	Substrate	[14]
Mitochondrial glutamate carrier 2 (SLC25A18)	DT3VZJO	GHC2_HUMAN	Substrate	[15]
Excitatory amino acid transporter 5 (SLC1A7)	DTBGZ8H	EAA5_HUMAN	Substrate	[12]
Vesicular glutamate transporter 3 (SLC17A8)	DTAGDH7	VGLU3_HUMAN	Substrate	[13]
Excitatory amino acid transporter 2 (SLC1A2)	DT0VAI5	EAA2_HUMAN	Substrate	[16]
Excitatory amino acid transporter 3 (SLC1A1)	DTJIRMD	EAA3_HUMAN	Substrate	[17]
Organic anion transporter 4 (SLC22A11)	DT06JWZ	S22AB_HUMAN	Substrate	[18]
Organic anion transporting polypeptide 2B1 (SLCO2B1)	DTPFTEQ	SO2B1_HUMAN	Substrate	[19]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1369).
2	Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs. 2008 Sep;13(3):511-22.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia pati... Am J Psychiatry. 2008 Dec;165(12):1594-603.
5	SLC22A13 catalyses unidirectional efflux of aspartate and glutamate at the basolateral membrane of type A intercalated cells in the renal collecting duct. Biochem J. 2014 Jan 15;457(2):243-51.
6	The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate. J Biol Chem. 2017 Aug 25;292(34):14240-14249.
7	Epigenetic upregulation and functional role of the mitochondrial aspartate/glutamate carrier isoform 1 in hepatocellular carcinoma. Biochim Biophys Acta Mol Basis Dis. 2019 Jan;1865(1):38-47.
8	Novel cystine transporter in renal proximal tubule identified as a missing partner of cystinuria-related plasma membrane protein rBAT/SLC3A1. Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):775-80.
9	Mitochondrial Aspartate/Glutamate Carrier SLC25A12 and Autism Spectrum Disorder: a Meta-Analysis. Mol Neurobiol. 2016 Apr;53(3):1579-1588.
10	Structural modeling of a novel SLC38A8 mutation that causes foveal hypoplasia. Mol Genet Genomic Med. 2017 Feb 26;5(3):202-209.
11	The neuronal and astrocytic protein SLC38A10 transports glutamine, glutamate, and aspartate, suggesting a role in neurotransmission. FEBS Open Bio. 2017 Apr 26;7(6):730-746.
12	The SLC1 high-affinity glutamate and neutral amino acid transporter family. Mol Aspects Med. 2013 Apr-Jun;34(2-3):108-20.
13	Molecular pharmacology of glutamate transporters, EAATs and VGLUTs. Brain Res Brain Res Rev. 2004 Jul;45(3):250-65.
14	Impaired mitochondrial glutamate transport in autosomal recessive neonatal myoclonic epilepsy. Am J Hum Genet. 2005 Feb;76(2):334-9.
15	The ABCs of membrane transporters in health and disease (SLC series): Introduction. Molecular Aspects of Medicine, 2013, 34(2-3):95-107. (GeneName=SLC25A18)
16	EAAT2 (GLT-1; slc1a2) glutamate transporters reconstituted in liposomes argues against heteroexchange being substantially faster than net uptake. J Neurosci. 2014 Oct 1;34(40):13472-85.
17	Loss-of-function mutations in the glutamate transporter SLC1A1 cause human dicarboxylic aminoaciduria. J Clin Invest. 2011 Jan;121(1):446-53.
18	The role of the intracellular glutamate gradient in driving organic anion transporter function.
19	The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.60.1.20)
20	Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71.
21	Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
22	Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
23	Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans. Xenobiotica. 2007 Apr;37(4):416-26.
24	Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76.
25	Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther. 2004 Mar;308(3):1021-9.
26	Inhibitory effects of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic anion transporter 4. J Pharm Pharmacol. 2006 Nov;58(11):1499-505.
27	Cellular Uptake of Levocetirizine by Organic Anion Transporter 4. J Pharm Sci. 2017 Sep;106(9):2895-2898.
28	Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers. Pharm Res. 2008 Mar;25(3):639-46.
29	Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60.
30	Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP. J Pharm Sci. 2017 Sep;106(9):2688-2694.
31	Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
32	Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45.
33	Human platelets express organic anion-transporting peptide 2B1, an uptake transporter for atorvastatin. Drug Metab Dispos. 2009 May;37(5):1129-37.
34	pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm. 2011 Aug 1;8(4):1303-13.
35	Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006 Jul;34(7):1229-36.
36	Drug Interactions in Infectious Diseases.
37	Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
38	Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos. 2007 Aug;35(8):1308-14.
39	Type 1 sodium-dependent phosphate transporter (SLC17A1 Protein) is a Cl(-)-dependent urate exporter. J Biol Chem. 2010 Aug 20;285(34):26107-13.
40	SLC17: a functionally diverse family of organic anion transporters. Mol Aspects Med. 2013 Apr-Jun;34(2-3):350-9.
41	How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
42	Amphetamine inhibits the N-methyl-D-aspartate receptor-mediated responses by directly interacting with the receptor/channel complex. J Pharmacol Exp Ther. 2002 Mar;300(3):1008-16.
43	Ketamine modulates theta and gamma oscillations. J Cogn Neurosci. 2010 Jul;22(7):1452-64.
44	Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor. J Med Chem. 2008 Mar 27;51(6):1534-45.
45	The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S23-32.
46	Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
47	Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20.
48	Magnesium sulfate diminishes the effects of amide local anesthetics in rat sciatic-nerve block. Reg Anesth Pain Med. 2007 Jul-Aug;32(4):288-95.
49	Emerging drugs for acute ischemic stroke. Expert Opin Emerg Drugs. 2009 Mar;14(1):33-42.
50	Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine. Pain. 2009 Apr;142(3):225-35.